Abstract
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10−8 to P = 2.7 × 10−24). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Eeles, R.A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316–321 (2008).
Al Olama, A.A. et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 41, 1058–1060 (2009).
Eeles, R.A. et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41, 1116–1121 (2009).
Varghese, J.S. & Easton, D.F. Genome-wide association studies in common cancers–what have we learnt? Curr. Opin. Genet. Dev. 20, 201–209 (2010).
Park, J.H. et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42, 570–575 (2010).
Schumacher, F.R. et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet. (in the press).
Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221–227 (2009).
Cropp, C.D. et al. Genome-wide linkage scan for prostate cancer susceptibility in finland: evidence for a novel locus on 2q37.2 and confirmation of signal on 17q21-q22. Int. J. Cancer published online, doi:10.1002/ijc.25906 (20 April 2011).
Filion, G.J. et al. A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol. Cell. Biol. 26, 169–181 (2006).
Oikawa, Y., Matsuda, E., Nishii, T., Ishida, Y. & Kawaichi, M. Down-regulation of CIBZ, a novel substrate of caspase-3, induces apoptosis. J. Biol. Chem. 283, 14242–14247 (2008).
Gudbjartsson, D.F. et al. Many sequence variants affecting diversity of adult human height. Nat. Genet. 40, 609–615 (2008).
Soranzo, N. et al. Meta-analysis of genome-wide scans for human adult stature identifies novel loci and associations with measures of skeletal frame size. PLoS Genet. 5, e100445 (2009).
Zuccolo, L. et al. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 17, 2325–2336 (2008).
Theodorou, V. et al. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 23, 6047–6055 (2004).
Ropiquet, F., Giri, D., Kwabi-Addo, B., Schmidt, K. & Ittmann, M. FGF-10 is expressed at low levels in the human prostate. Prostate 44, 334–338 (2000).
Thomson, A.A. & Cunha, G.R. Prostatic growth and development are regulated by FGF10. Development 126, 3693–3701 (1999).
Suomela, S. et al. CCHCR1 is up-regulated in skin cancer and associated with EGFR expression. PLoS ONE 4, e6030 (2009).
Sugawara, T., Shimizu, H., Hoshi, N., Nakajima, A. & Fujimoto, S. Steroidogenic acute regulatory protein-binding protein cloned by a yeast two-hybrid system. J. Biol. Chem. 278, 42487–42494 (2003).
Corbi, N. et al. RNA polymerase II subunit 3 is retained in the cytoplasm by its interaction with HCR, the psoriasis vulgaris candidate gene product. J. Cell Sci. 118, 4253–4260 (2005).
Donovan, J. et al. Prostate testing for cancer and Treatment (ProtecT) feasibility study. Health Technol. Assess. 7, 1–88 (2003).
Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
Aulchenko, Y.S., Ripke, S., Isaacs, A. & van Duijn, C.M. GenABEL: an R library for genome-wide association analysis. Bioinformatics 23, 1294–1296 (2007).
Aulchenko, Y.S., Struchalin, M.V. & van Duijn, C.M. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11, 134 (2010).
Acknowledgements
The full acknowledgments are detailed in the Supplementary Note.
Author information
Authors and Affiliations
Consortia
Contributions
R.A.E. and D.F.E. designed the study and are joint principal investigators (PIs) on the GWAS. R.A.E. is the PI of the UK Genetic Prostate Cancer Study (UKGPCS) and project managed the overall study. Z.K.-J., R.A.E., D.F.E. and A.A.A.O. wrote the paper, and Z.K.-J. coordinated and managed the stage 3 and the PRACTICAL stage 4 genotyping. Z.K.-J., D.A.L., M.T., E.J.S. and N.M. coordinated sample collation for stage 3 and the PRACTICAL stage 4 set genotyped in the UK. A.A.A.O. and D.F.E. performed the statistical analyses. S.B. collated the dataset. G.G.G., J.L.H., D.R.E. and G.S. are PIs of the Australian studies. M.C. Southey manages the molecular work. J. Schleutker is PI of the Tampere study. T.W. collected clinical data, performed sample selection and collated data. T.L.J.T. coordinated sample collection. M.W. is the PI of the CPCS1 and CPCS2 studies. P. Klarskov, B.G.E., M.A.R., A.T.-H. and S.E.B. have collected samples and data and contributed to the genotyping of this study. F.C.H., D.E.N. and J.L. Donovan are joint PIs of ProtecT. A.L. is the study coordinator and M.D. the database manager. A.C. assisted with sample selection, retrieval and processing. D.A. and J.V. are PIs of the ATBC Study and were responsible for the original collection of the ATBC DNA samples. S.C. was responsible for assembly and genotyping. S.I.B. is the PI of the PLCO study, A.G. is the PI for the St. Louis screening center for PLCO and M.Y. oversaw the genotyping for PLCO. H.B. is the PI of the ESTHER study; D.R. and C.S. contributed to design and data collection; and H.M. is the study coordinator. C.C. and J.L.H. are PIs of the Poland study. C.C. and D.W. genotyped the samples. C.M. and W.V. are PIs of the Ulm study. A.E.R. identified and collected clinical material, processed samples, undertook genotyping and collated data. T. Dörk is the PI of the Hannover Prostate Cancer Study. A.M. and J.S. coordinated sample collation, provided molecular advice and conducted molecular work. J.L. Dickinson is the PI of the Tasprac study. J.R.M. performed the Tasmanian genotyping and collated data; B.P. provided molecular advice and assistance with collating data. P. Kraft coordinated data collection and management for the HPFS. T.F.Ø. and K.D.S. are PIs of the Aarhus study. M.B. coordinated sample collection and registration of clinical data. K.D.S. led the sample genotyping. E.R. is PI of EPIC; D.C. and F.C. typed EPIC samples. T.K. is the PI of the EPIC-Oxford cohort and collected clinical material. R.T. collated data. S.M.G. and M.J.T. are the PIs of the ACS CPS-II study, and W.R.D. is the data manager for this study. B.E.H. and L.L.M. are the PIs of the MEC, and C.A.H. and F.S. are co-investigators (CIs). Y.-J.L. and H.-W.Z. are joint PIs of CHSH, Y.-J.L. is study coordinator and H.-W.Z. participated in and closely supervised the CHSH study. J.L.S. is the PI of the Fred Hutchinson study and E.A.O. is PI of the NHGRI genotyping for PROGRESS, and L.M.F. and J.S.K. coordinated data collation. S.A.I. is the PI of the USC study, E.M.J. is the PI of the NCCC study and M.C. Stern and R.C. led the genotyping of both studies. S.N.T. and D.S. are PIs of the Mayo clinic study, and S.K.D. coordinated data collation. J.Y.P. is the PI of the Moffitt study, and T.A.S. and H.-Y.L. are contributors to this study. J.A.C. and A.B.S. are PIs of the molecular genetics arm of the Proscan study, and with J.B. and F.L. coordinated all risk factor data and genetic data collection for prostate cancer cases from Proscan, the Brisbane Retrospective Study, the Australian Prostate Cancer BioResource Brisbane node and controls from two Queensland control sets. S.C., J.A. and R.A.F.G. are PIs of the Proscan study and were responsible for the original platform study initiation, conceptualization and collection of the Proscan study cases. K.A.C. is the PI of the FMHS study. L.C.-A. is the PI of the Utah study, and R.K. is the PI of the PCMUS study. H.G. is PI of CAPS and STHM1; F.K. directed the genotyping. D.J.H. directs the CPSII. S.I. directs the NCCC. R.B.H. and G.A. direct the PLCO. P.P. directs the SEARCH study. T.H. is PI of the Japan study. K.M. is co-PI of the PCRF study which provided some controls for the UK sets. A.T., A.D.J., A.L.H., L.T.O., R.A.W., E.C.P., E.J.S., D.P.D., A.H., R.A.H., V.S.K., C.C.P., N.V.A., C.J.W., A.T., T.C., C.O., L.N.K., L.L.M., A.A., A.C., D.M.K., E.M.K., A.D.J., A. Shahabi, T.A.S., J.P.S., S.C., J.A., R.A.F.G., J.B., F.L., A.P., B.P., J. Serth, F.W., T. Dadaev, M.G., J.M., C.S.C., B.G.N., M.A., S.L., S.G., L.F., S.K., S.K.M., R.A.S., A.R., N.T., S.N., G.-W.C., A.M., A.E.R., K.L., A.M.R., E.M.L., J.F., H.K. and C.S. identified and collected clinical material, and V.M. coordinated data collation. Other members of the UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, The UK ProtecT Study Collaborators and The PRACTICAL Consortium members (membership lists provided in the Supplementary Note) collected clinical samples, assisted in genotyping and provided data management. All study acronyms are defined in the Supplementary Note.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
A full list of members is provided in the Supplementary Note.
A full list of members is provided in the Supplementary Note.
A full list of members is provided in the Supplementary Note.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1 and 2, Supplementary Tables 1–5 and Supplementary Note (PDF 688 kb)
Rights and permissions
About this article
Cite this article
Kote-Jarai, Z., Olama, A., Giles, G. et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43, 785–791 (2011). https://doi.org/10.1038/ng.882
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.882
This article is cited by
-
Possible prognostic impact of PKCι genetic variants in prostate cancer
Cancer Cell International (2024)
-
Association of genetic variants with prostate cancer in Africa: a concise review
Egyptian Journal of Medical Human Genetics (2021)
-
Association between metformin medication, genetic variation and prostate cancer risk
Prostate Cancer and Prostatic Diseases (2021)
-
Negative associations between the has-miR-27a and hsa-miR-125a gene variations and prostate cancer susceptibility
Molecular Biology Reports (2020)
-
Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population
Pathology & Oncology Research (2020)